Top advances of the year: Neoadjuvant immunotherapy in melanoma Editorial

  

Authors:	Chen, M. F.; Postow, M. A.
Title:	Top advances of the year: Neoadjuvant immunotherapy in melanoma
Keywords:	event free survival; treatment outcome; unclassified drug; gene mutation; overall survival; monotherapy; side effect; systemic therapy; note; adjuvant therapy; neoadjuvant therapy; temozolomide; cancer staging; lymph node metastasis; ipilimumab; cancer immunotherapy; melanoma; combination chemotherapy; drug development; distant metastasis; lymphocyte activation; adverse outcome; immunotherapy; drug therapy; cytotoxic t lymphocyte antigen 4; b raf kinase; adverse drug reaction; therapy; neoadjuvant; recurrence free survival; programmed death 1 receptor; pathological complete response; clinical trial (topic); lymphocyte activation gene 3 protein; immune checkpoint inhibitor; response evaluation criteria in solid tumors; nivolumab; metastasis free survival; lenvatinib; human; article; pembrolizumab; camrelizumab; rivoceranib; relatlimab; dostarlimab; checkpoint inhibitor therapy; nivolumab plus relatlimab; cobolimab; etimumotide; imsamotide; neovax
Journal Title:	Cancer
Volume:	131
Issue:	9
ISSN:	0008-543X
Publisher:	Wiley Blackwell
Date Published:	2025-05-01
Start Page:	e35877
Language:	English
DOI:	10.1002/cncr.35877
PUBMED:	40305630
PROVIDER:	scopus
DOI/URL:	https://www.scopus.com/inward/record.uri?eid=2-s2.0-105004173662&doi=10.1002%2fcncr.35877&partnerID=40&md5=407ccf14ec147558433fb578caa54eb5
Notes:	The MSK Cancer Center Support Grant (P30 CA008748) is acknowledge in the PDF -- Corresponding authors is MSK author: Monica F. Chen -- Source: Scopus

https://synapse.mskcc.org/synapse/works/has_related_data_chk/225393